Masimo Corporation

717 articles about Masimo Corporation

• Masimo Announces Select Preliminary Full-Year 2021 Financial Results and 2022 Guidance

  1/11/2022

  Masimo Corporation announced select preliminary financial and operational results for the full-year ended January 1, 2022 and provided estimates for its full-year 2022 financial guidance.

• New Study Suggests That Masimo SedLine® Brain Function Monitoring May Aid Early Identification of Patients at Risk of Developing Postoperative Delirium

  12/13/2021

  Masimo announced the findings of a prospective study published in Anesthesia & Analgesia in which Dr. Claudia Spies and colleagues investigated the relationship between parameters derived from electroencephalogram spectra, measured using Masimo SedLine® Brain Function Monitoring, and postoperative delirium in older patients undergoing elective surgery.

• Masimo Rad-G® Helps Clinicians Identify Pediatric Pneumonia in Large Field Trial in India

  11/29/2021

  Masimo announced the findings of a study published in Clinical Medicine Insights: Pediatrics in which Dr. Harish Kumar and colleagues at IPE Global in New Delhi, India reported on their experience using the Masimo Rad-G® Pulse Oximeter to aid health providers in pneumonia case detection and management in more than 4,500 children under five years who presented with symptoms of acute respiratory infection.

• Masimo to Present in Piper Sandler 33rd Annual Healthcare Conference

  11/23/2021

  Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Piper Sandler 33rd Annual Healthcare Conference on Tuesday, November 30, 2021 at 2:00 p.m. Eastern Time.

• New Study Finds That Use of Masimo SedLine® PSi and DSA May Significantly Reduce Postoperative Delirium

  11/15/2021

  Masimo announced the findings of a prospective study published in Frontiers in Neurology in which Dr. Na Xu and colleagues at Capital Medical University in Beijing investigated whether general anesthesia guided by Masimo SedLine® Brain Function Monitoring parameters on Root® could reduce the incidence of postoperative delirium in patients undergoing carotid endarterectomy.

• Masimo to Present in Stifel 2021 Virtual Healthcare Conference

  11/11/2021

  Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 4:00 p.m. Eastern Time.

• Masimo Root® with a Multimodal Brain Monitoring Algorithm May Improve Postoperative Neurocognition in Elderly Patients

  11/8/2021

  Masimo announced the findings of a prospective study published in Frontiers in Aging Neuroscience in which Dr. Shuyi Yang and colleagues at Capital Medical University in Beijing investigated whether Masimo Root® with a multimodal brain monitoring algorithm to manage anesthesia during spinal surgery could improve postoperative cognitive function.

• Masimo Launches Dual SET® Pulse Oximetry

  11/1/2021

  Masimo announced Dual SET® Pulse Oximetry for Root®, a highly versatile patient monitoring and connectivity hub.

• Masimo to Report Third Quarter 2021 Financial Results After Market Close on Tuesday, October 26

  10/12/2021

  Masimo will release third quarter 2021 financial results for the period ended October 2, 2021, after the market closes on Tuesday, October 26, 2021.

• New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates

  9/27/2021

  Masimo announced the findings of a study published in the European Journal of Pediatrics in which Dr. Masashi Hotta and colleagues at the Osaka Women’s and Children’s Hospital in Japan found that the Masimo EMMA® Portable Capnograph “may be considered an effective monitoring device” for mechanically ventilated preterm infants.1.

• Masimo CEO Joe Kiani Appointed to President’s Council of Advisors on Science and Technology

  9/22/2021

  Masimo announced that Founder, Chairman, and CEO Joe Kiani has been appointed by President Joe Biden to the President’s Council of Advisors on Science and Technology.

• Masimo Launches Single-patient-use rainbow® SuperSensor™

  9/13/2021

  Masimo announced the CE marking and commercial launch in Europe of the single-patient-use adhesive rainbow® SuperSensor™, compatible for use with both Masimo and third-party monitors with Masimo rainbow® technology inside.

• Masimo to Present in Morgan Stanley 19th Annual Global Healthcare Conference

  9/8/2021

  Masimo announced that its management is scheduled to participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 4:15 p.m. Eastern Time.

• New Study Investigates the Ability of Masimo ORi™ to Provide Early Warning of Hypoxemia During Endotracheal Intubation in ICU Patients

  9/6/2021

  Masimo announced the findings of a prospective, blinded observational study published in Annals of Intensive Care in which Dr. Jean-Baptiste Lascarrou and colleagues at the Centre Hospitalier Universitaire in Nantes, France evaluated the ability of Masimo ORi™ to predict mild hypoxemia during endotracheal intubation in ICU patients.

• New Study Evaluates the Use of Masimo PVi® to Monitor Volume Status in Spontaneously Breathing Hemodialysis Patients

  8/23/2021

  Masimo announced the findings of a study published in the Turkish Journal of Emergency Medicine in which Drs. Seda Dağar and Hüseyin Uzunosmanoğlu at the Kecioren Training and Research Hospital in Ankara, Turkey investigated the role that noninvasive, continuous Masimo PVi® might play in monitoring volume status and volume changes in spontaneously breathing patients undergoing hemodialysis.

• New Study Evaluates the Use of Masimo Bridge® As an Alternative to Opioids

  8/16/2021

  Masimo announced the findings of a study published in the Journal of Pain & Relief in which Dr. Jacques Chelly and colleagues at the University of Pittsburgh investigated the utility of Masimo Bridge®, an auricular field nerve stimulator, in reducing postoperative opioid requirements in patients undergoing kidney donor surgery.

• Masimo Reports Second Quarter 2021 Financial Results

  7/27/2021

  Masimo announced its financial results for the second quarter of 2021, ended July 3, 2021.

• Masimo Introduces the MX-7™ rainbow SET® Technology Board for Original Equipment Manufacturing Partners

  7/19/2021

  Masimo Introduces the MX-7™ rainbow SET ® Technology Board for Original Equipment Manufacturing Partners

• Masimo to Report Second Quarter 2021 Financial Results after Market Close on Tuesday, July 27

  7/13/2021

  Masimo (NASDAQ: MASI) will release second quarter 2021 financial results for the period ended July 3, 2021, after the market closes on Tuesday, July 27, 2021.

• New Study Evaluates the Ability of Masimo SedLine® Brain Function Monitoring to Predict Neurological Outcomes and Long-term Survival in Post-Cardiac Arrest ICU Patients

  7/6/2021

  Researchers Found That the Combination of Two SedLine Parameters, Patient State Index (PSi) and Suppression Ratio (SR), Had High Predictability for Mortality 180 Days After Cardiac Arrest.